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Abstract
Background: Cysteamine, an anti-oxidant aminothiol, is the treatment of choice for nephropathic cystinosis, a rare
lysosomal storage disease. Cysteamine is a chemo-sensitization and radioprotection agent and its antitumor effects have
been investigated in various tumor cell lines and chemical induced carcinogenesis. Here, we investigated whether
cysteamine has anti-tumor and anti-metastatic effects in transplantable human pancreatic cancer, an aggressive metastatic
disease.
Methodology/Principal Findings: Cysteamine’s anti-invasion effects were studied by matrigel invasion and cell migration
assays in 10 pancreatic cancer cell lines. To study mechanism of action, we examined cell viability and matrix
metalloproteinases (MMPs) activity in the cysteamine-treated cells. We also examined cysteamine’s anti-metastasis effect in
two orthotopic murine models of human pancreatic cancer by measuring peritoneal metastasis and survival of animals.
Cysteamine inhibited both migration and invasion of all ten pancreatic cancer cell lines at concentrations (,25 mM) that
caused no toxicity to cells. It significantly decreased MMPs activity (IC50 38–460 mM) and zymographic gelatinase activity in a
dose dependent manner in vitro and in vivo; while mRNA and protein levels of MMP-9, MMP-12 and MMP-14 were slightly
increased using the highest cysteamine concentration. In vivo, cysteamine significantly decreased metastasis in two
established pancreatic tumor models, although it did not affect the size of primary tumors. Additionally, cysteamine
prolonged survival of mice in a dose-dependent manner without causing any toxicity. Similar to the in vitro results, MMP
activity was significantly decreased in animal tumors treated with cysteamine. Cysteamine had no clinical or preclinical
adverse effects in the host even at the highest dose.
Conclusions/Significance: Our results suggest that cysteamine, an agent with a proven safety profile, may be useful for
inhibition of metastasis and prolonging the survival of a host with pancreatic cancer.
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Introduction
Cysteamine is a simple aminothiol and anti-oxidant that has
potential for the treatment of radiation sickness, neurological
disorders and cancer. Cysteamine is also approved by the Food
and Drug Administration for the treatment of patients with
cystinosis, an autosomal recessive disorder characterized by
accumulation of cystine in lysosomes [1,2]. The pharmacokinetics
and adverse effects of cysteamine have been very well studied [3–
5]. In the cancer field, many studies have reported anti-cancer
effects of cysteamine with respect to cancer development and
proliferation. Cysteamine prevented not only the development of
metaplasia but also carcinogenesis of mammary tumor and gastric
cancers induced chemically and by radiation [6–8]. Cysteamine by
itself or conjugated with nanoparticles or other compounds
suppress cancer cell proliferation derived from neural neoplastic
tumors [9], SMMC-7721 hepatocellular carcinoma [10], breast
cancer [11], and melanoma cell lines [12] in vitro. These derivatives
seem to inhibit the growth of cancer cells, synergize the effect of
other anti-cancer drugs, induce apoptosis or exert cytotoxic effects
on DNA replication. Cysteamine is also found to exert a biphasic
effect on the autophagy by inducing the formation of autophago-
somes at early time points but autophagic degradation at later time
points [13]. Cysteamine is known to inhibit intestinal neoplasia
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34437induced by X-irradiation [6] and gastric carcinogenesis induced by
N-methyl-N’-nitrosoguanidine in rats [9,14]. However, there is no
report in the literature addressing the anti-invasive or anti-
metastatic effects of cysteamine in human cancers.
Pancreatic cancer is characterized by local invasion of adjacent
structures and metastasis to lymph nodes and liver in the very early
stages. At the time of diagnosis, most pancreatic cancers are
already metastatic, making the tumor unresectable [15,16].
Therefore, efforts must be focused on not only targeting the
primary tumor but also controlling metastases to successfully treat
pancreatic cancer.
Matrix metalloproteinases (MMPs) are a group of zinc-
dependent endopeptidases implicated in mammalian angiogenesis,
wound healing, and tissue remodeling [17]. In cancer, MMPs play
an important role in cell invasion and metastasis by controlling
degradation of the extracellular matrix [18]. In particular, MMP-9
plays a central role in pancreatic cancer invasion, and its inhibition
decreases liver metastasis of pancreatic cancer [15,19]. Hence,
many MMP inhibitors of broad to narrow specificity have been
investigated for their anti-cancer effects. Some MMP inhibitors
successfully suppress tumor growth and metastasis in animal
models [20–22], but they fail to show anti-cancer effects in clinical
Figure 1. Cysteamine inhibited cell migration and invasion of pancreatic cancer cell lines. A. For the matrigel invasion assay, cells were
incubated with increasing concentrations of cysteamine in the matrigel chamber for 24 hours. The number of invaded cells on the opposite side of
the membrane was counted. B and C. Wound healing assay. Cells were cultured until confluent and scratched using a sterilized yellow tip. They were
incubated for 24 hours with 0–5 mM of cysteamine and the area of the wound between cell layers was measured. The black horizontal lines in figure
(vehicle) depict the area at time 0 when wound was made and indicate the area of the wound when cells were scratched (B). D. For cell viability assay,
pancreatic cancer cells were incubated with various concentrations of cysteamine and live cell number was counted at 24 and 48 hours. Data are
expressed as mean 6 S.D. of triplicate determinations. Statistical significances are shown by {:P ,0.01 and {:P ,0.001.
doi:10.1371/journal.pone.0034437.g001
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involving severe joint and muscle pain [23,24]. Therefore, it is
important to identify MMP inhibitors with little or no side effects.
In the present study, we examined the anti-invasive effects of
cysteamine, which has an excellent safety profile, in pancreatic
cancer cell lines in vitro. We also investigated the anti-metastastic-
effect of cysteamine in animal models of human pancreatic cancer,
specifically determining if it can decrease cancer metastasis in
orthotopic pancreatic cancer models in immunodeficient mice.
Finally, the safety of subcutaneous cysteamine was assessed in
tumor-bearing mice.
Materials and Methods
Cell culture and reagents
Pancreatic cancer cell lines (HS766T, MIA-PaCa2, Panc-1,
ASPC-1, PK-1, Mpanc96, BxPC-3, KLM, HPAF-II, and
SW1990) were obtained from the American Type Culture
Collection (Manassas, VA). Cysteamine hydrochloride was
purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in
distilled water.
Figure 2. Cysteamine inhibited MMP activity in pancreatic cancer cells. A. To measure total MMPs activity in pancreatic cancer cell lines, cells
were incubated with 0–5 mM of cysteamine for 24 hours, total protein extracted and the activity measured using fluorogenic substrate. The effect of
cysteamine on MMP-9 at protein level by ELISA (B), MMP-9, MMP-12 and MMP-14 mRNA levels (C) and gelatinase zymographic activities (D) was
determined after incubating pancreatic cancer cells with cysteamine for 24 hours. MMP-9 activity was determined by ELISA and mRNA by qRT-PCR. b-
actin was used for a reference gene in qRT-PCR. Data represent MMP-9 protein in pg/mg total cell lysate and RFU percent ratio of mRNA/ b -actin. Data
are expressed as mean 6 S.D. of triplicate determinations and experiments were repeated three times. Statistical significances are shown by *:
P,0.05, {:p ,0.01 and {:P ,0.001.
doi:10.1371/journal.pone.0034437.g002
Figure 3. Cysteamine inhibited MMP enzyme activities in vitro. IC50 of MMPs was determined by incubating each MMP enzyme with various
concentrations of cysteamine and batimastat in a fluorimetric assay as described in materials and methods. IC50 is the concentration of inhibitor at
which 50% inhibition of proteolysis occurs.
doi:10.1371/journal.pone.0034437.g003
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Cell migration assay is a classical wound healing assay [25]. For
this assay, cells were cultured in 10 cm petri dishes until they were
completely confluent. Cell monolayers were scraped with a sterile
yellow micropipette tip and washed with PBS three times; the cells
were then cultured in medium containing 0–5 mM of cysteamine
for 24 hours. Five random fields were selected and pictures were
taken using an inverted microscope. The average area (mm
2)o f
the gap between the cell layers was calculated using IPLab imaging
software (BD Biosciences-Bioimaging, Rockville, MD).
Matrigel invasion assay
Cell invasion was assayed in BD BioCoat Matrigel invasion
chambers (BD Biosciences; 24 wells, 8 mm pore size) as described
previously [26]. Briefly, cells were incubated with different
concentrations of cysteamine (0–5 mM) for 24 hours. Non-
invaded cells were removed from the upper surface of the
membrane with a cotton swab, and cells on the lower surface of
the membrane were fixed and stained with H&E. Three random
fields per chamber were counted. Data were shown as mean 6
S.D. of triplicate determinations.
Cell viability assay
Cell viability of pancreatic cancer cell lines was measured by
counting viable cell numbers. Briefly, 3610
5 cells were seeded per
well in a 6-well plate with 2.0 milliliter complete medium and
incubated overnight for plating. The cells were treated with
different concentrations of cysteamine for 24–48 hours. After
incubation, cells were detached with trypsin, washed and stained
with 0.4% trypan blue. Cell number was manually counted using a
hemocytometer and presented as number of viable cells per
milliliter.
Measurement of MMP activity
MMPs activity was measured by Mca-KPLGL-Dpa-AR-NH2
Fluorogenic Peptide Substrate (R&D systems, Emeryville, CA).
Total cell protein from each pancreatic cancer cell line was
collected using lysis buffer (containing 50 mM Tris-HCl, 10 mM
CaCl2, 0.05% Brij35 and 0.25% Triton-X) without an MMP
inhibitor. Substrate and 10 mg of total cell protein in the buffer
were mixed in a black-wall 96-well plate. After 1 hour incubation,
fluorescence units were determined using excitation/emis-
sion=320/405 nm.
Substrate gel zymographic assay for MMP activity
Gelatin gel zymography was performed on cell lysates from
HS7666 and MIA-PaCa2 pancreatic cancer cell line with or
without culture with different concentration of cysteamine
essentially as described by D’Angelo et al [27]. Briefly, 50 mgo f
total protein was electrophoresed on 10% SDS-PAGE containing
0.1% gelatin as substrate. After washing with 1% Triton X-100 in
50 mM Tris/HCl, pH 7.5 for 1 hr to remove SDS, the gels were
incubated overnight at 37
uC in 50 mM Tris/HCl, pH 7.5,
containing 150 mM NaCl, 10 mM CaCl2 and 0.1% Triton X-
100, prior to staining with simply blue safe stain. The gels were
washed with deionized water at room temperature. Gelatin-
degrading enzymes were identified by their ability to digest gelatin
Figure 4. Cysteamine inhibited primary tumors and metastatic lesions in an orthotopic pancreatic cancer in vivo. HS766T and MIA-
PaCa2 cells (2610
6) were implanted directly into the pancreas of 5–6 week-old female nude nu/nu mice and then peritoneal cavity and skin were
closed using clips. Increasing doses of cysteamine were injected s.c. as described in materials and methods. Primary tumors and metastatic lesions of
$ 5 mm were counted in vehicle and cysteamine treated mice. a:P ,0.05, b:P ,0.01 and c:P ,0.05, d: P,0.001. +: moderate ascites, ++: severe
ascites, –: no ascites.
doi:10.1371/journal.pone.0034437.g004
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intensities were quantified by scanning densitometric analysis and
normalized to cell number.
Quantitative Reverse transcription-PCR
Quantitative reverse transcription-PCR (qRT-PCR) was per-
formed as described previously using QuantiTect SYBR Green
PCR Kits (QIAGEN, Valencia, CA) [28]. Gene specific primers
for human MMP-9, MMP-12, MMP-14 and b-actin were either
Figure 5. Cysteamine decreased metastasis and prolonged survival in an orthotopic pancreatic cancer mouse model. HS766T and
MIA-PaCa2 cells (2610
6) were implanted directly into the pancreas of 5–6 week-old female nude nu/nu mice and then peritoneal cavity and skin were
closed using clips. From day 4 after tumor implantation, mice were treated twice a day with vehicle or 25, 100, 250 mg/kg/day of cysteamine until
the end of the experiment. The mice with tumors were sacrificed 4 weeks after cell implantation. A. A representative mouse from each treatment
group harboring MIA-PaCa2 tumor is shown. Yellow arrows indicate primary tumors in the pancreas and blue triangles indicate metastatic lesions. In
another experiment, control and cysteamine treated mice were followed for survival. Kaplan-Meier survival curves of mice harboring HS766T (B) and
MIA-PaCa2 (C) tumors.
doi:10.1371/journal.pone.0034437.g005
Figure 6. Measurement of body weight of control and cysteamine treated mice. Mice with HS766T tumors were treated with increasing
doses of cysteamine and body weights were measured at day 10 and day 25 after tumor implantation. There was no significant difference among
treatment groups.
doi:10.1371/journal.pone.0034437.g006
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facility. Gene expression was normalized to b-actin before the fold
change in gene expression was determined.
Enzyme-Linked ImmunoSorbent Assay (ELISA)
The MMP-9 protein level was determined using Human total
MMP-9 DuoSet kit (R&D systems, Emeryville, CA) following the
manufacturer’s instruction. Ten microgram of total protein was
aliquoted in each well and the MMP-9 concentration was
determined by the colorimetric method.
IC50 of cysteamine against MMPs activity
IC50 of cysteamine and batimastat was determined using a
fluorimetric MMP inhibitor profiling kit (Enzo Life Science,
Farmingdale, NY), following the manufacturer’s instruction.
Briefly, each MMP enzyme was mixed with various concentrations
of cysteamine and batimastat in a black-wall 96 well plate and
incubated for 30 minutes. After administration of fluorogenic
substrate, a velocity of fluorescent increase was measured using
excitation/emission=320/405 nm.
Measurement of metastasis, survival and body weight of
animals implanted with orthotopic pancreatic cancer in
mouse model
Female nude nu/nu mice between ages 5 and 6 weeks were
maintained in a barrier facility in HEPA-filtered rack. All animal
studies were conducted under approved protocol #2000–06 by
the CBER Institutional Animal Care and Use Committee in
accordance with the principles and procedures outlined in the NIH
Guideline for the Care and Use of Laboratory Animals. For orthotopic
tumor cell injection, the pancreas was carefully exposed, and
2.0610
6 of MIA-PaCa2 and HS766T cells were injected into the
organ. The pancreas was then returned to the peritoneal cavity,
and the abdominal wall and skin were closed with skin clips
[29,30]. From day 4 after tumor implantation, increasing doses of
cysteamine (0, 25, 100, or 250 mg/kg/day) were subcutaneously
injected twice a day until the end of the experiment. At day 30,
mice were sacrificed and the number of metastatic nodules visible
by naked eye and whose sizes were .5 mm in diameter counted.
The total weight of primary tumor and metastatic nodules were
also measured. Pictures were taken immediately after sacrificing
the animals. Additionally, mouse survival time was monitored in
an independent experiment. Mice were sacrificed when they had
severe ascites or cachexia. Mice in both tumor models were
weighed at day 10 and day 25 after Cysteamine treatment.
Measurement of enzymes in mouse serum
Mouse blood was collected from the tail vein. Serum levels of
alanine aminotransferase (ALT), creatine kinase (CK), aldolase
and creatinine (Cr) were measured using different kits obtained
from Pointe Scientific, Inc. (Canton, MI) and Caldon Biotech, Inc.
(Vista, Ca), following the manufacturer’s instruction.
MMP activity and MMP-9 expression in primary tumors
When mice were sacrificed at day 30, primary tumors were
collected. For extraction of total protein, the tumor was soaked
with lysis buffer and homogenized using TissueRuptor (QIAGEN);
the supernatant was collected. Total RNA was extracted using
Figure 7. Effect of cysteamine on serum enzymes and creatinine levels. Tumor bearing mice were treated with increasing doses of
cysteamine and serum was collected from tail veins twice, i.e., pre-cysteamine treatment (day 4) and post- treatment (day 18). Liver, muscle and
kidney function biomarkers were evaluated after cysteamine treatment. Alanine aminotransferase (ALT), creatine kinase (CK), aldolase, and creatinine
(Cr) were measured in each group. There were no significant differences among treatment groups.
doi:10.1371/journal.pone.0034437.g007
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the manufacturer’s instructions. MMP activity, gelatin hydrolyzing
MMP activity and the mRNA and protein levels of MMP-9 were
determined as mentioned above.
Statistical analysis
The data for enzymatic activity, ELISA, and qRT-PCR were
compared between each group by ANOVA. Survival curves were
generated by the Kaplan-Meier method and compared by using
the log-rank test.
Results
Cysteamine inhibits pancreatic cancer cell migration and
invasion without being cytotoxic to cells
We first examined the effect of cysteamine on pancreatic cancer
cell invasion using the matrigel invasion assay. For this assay, we
used 10 different pancreatic cancer cell lines in a matrigel invasion
chamber. As shown in Fig. 1A and Figure S1, cysteamine
inhibited cell invasion in a concentration dependent manner.
Even the lowest concentration of cysteamine (0.05 mM) signifi-
cantly inhibited cell invasion in all pancreatic cancer cell lines.
We next examined the effect of cysteamine on migration of
same 10 pancreatic cancer cell lines in the invasion assay. For the
migration assay, a wound healing assay was used. The represen-
tative pictures of cellular wound healing in HS766T cells are
shown in Figure 1B. Cell migration was significantly inhibited at
and above 0.05 mM of cysteamine in all 10 cell lines (Figure 1C
and Figure S2). The black horizontal lines in figure 1B (vehicle)
depict the area at time 0 when wound was made. Since cysteamine
mediated similar effects in all 10 cell lines in these assays, we
choose two random cell lines for all other assays.
We also examined the cytotoxicity of cysteamine against two
pancreatic cancer cell lines (HS766T and MIA-PaCa2). Number
of viable cells after 24 and 48 hour cysteamine treatment were
counted. Cysteamine showed cell toxicity at .12.5 mM concen-
tration in both cell lines tested but no evidence of toxicity was
observed at lower concentrations as number of viable cells were
similar to untreated cells (Figure 1D). These results suggest that
both cell migration and invasion were inhibited at a noncytotoxic
concentration of cysteamine.
Cysteamine inhibits MMP enzymatic activity in pancreatic
cancer cell lines
To investigate the mechanism of inhibition of cell migration and
invasion by cysteamine, we examined the effect of cysteamine on
MMP enzymatic activity. Cysteamine inhibited MMP activity in
two representative pancreatic cancer cell lines tested in a
Figure 8. Cysteamine decreased MMP activity in primary orthotopic tumors in mice. A. At day 30 after orthotopic implantation of
pancreatic cancer cells, tumors were collected, total protein extracted and MMP activity determined by using fluorogenic MMP substrate. B. MMP-9
mRNA levels were determined in total RNA extracted from tumors by qRT-PCR. b-actin was used for a reference gene. C. MMP-9 protein level was
determined by ELISA. D. Zymographic assay was performed in cysteamine treated tumors. Data are expressed as mean 6 S.D. of triplicate to
quadruplicate determinations. Experiment was repeated two times. Statistical significances are shown by *: P,0.05, {:p ,0.01 and {:P ,0.001.
doi:10.1371/journal.pone.0034437.g008
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concentration of cysteamine at which 50% MMP enzyme activity
(proteolysis) is inhibited} was calculated by ELISA (Figure 3).
Cysteamine directly inhibited each MMP enzymatic activity, with
an IC50 of 38–460 mM. Since MMP-9 plays a central role in
pancreatic cancer invasion, we examined its mRNA and protein
levels in both cell lines. In contrast to the enzymatic activity,
protein and mRNA levels of MMP-9 were modestly increased at
the highest concentration of cysteamine (5 mM) (Figure 2B and
2C). We also observed that mRNAs for two other MMPs (MMP-
12 and MMP-14) showed a modest increase similar to MMP-9 in
response to cysteamine treatment (Fig. 2C). In contrast, zymo-
graphic gelatin hydrolyzing activity results for MMP-9 differed
significantly from mRNA expression and both pro and active
MMP-9 activities decreased significantly in a dose dependent
manner (Fig 2D).
Cysteamine decreases metastasis and prolongs survival
of immunodeficient mice implanted orthotopically with
human pancreatic cancer
We investigated the anti-metastasis effect of cysteamine in two
orthotopic mouse models using human pancreatic cancer cell lines.
Mice were treated twice daily with cysteamine subcutaneously
from day 4 after tumor implantation until the end of the
experiment. At day 30, the number and weight of the primary
tumor and metastatic nodules were measured (Figure 4). In both
tumor models, the size and weight of the primary tumors did not
show any difference between control and treated groups.
However, cysteamine significantly decreased the number of
metastatic nodules in a dose-dependent manner. At the highest
dose (250 mg/kg/day), cysteamine significantly decreased the
number of metastases of HS766T tumor by ,90% (from 34 to
3.6). The total weight of metastatic nodules of MIA-PaCa2 tumor
was also decreased by ,90% at the highest dose. In addition, two
of 5 mice in the HS766T tumor model and 4 of 5 mice in MIA-
PaCa2 tumor model developed ascites in their peritoneal cavity.
However, no mice developed ascites at 100 and 250 mg/kg/day
dose in either tumor model. A representative picture of four mice
with the MIA-PaCa2 tumor is shown in Figure 5A. We also
compared the survival of mice among different treatment groups.
Mouse survival time was significantly prolonged when treated with
$100 mg/kg/day cysteamine in both tumor models (Figure 5B
and 5C).
We also carefully monitored the general condition and body
weight of mice throughout the experimental period. There was no
significant difference in general appearance and body weight
among four groups of animals in both tumor models (Figure 6).
Similarly, there was no alteration in serum enzymes representing
liver function (ALT) or muscle damage (Aldolase) nor evidence of
skeletal muscle damage or kidney function (creatinine kinase and
creatinine) in the cysteamine-treated groups (Figure 7). Moreover,
no organ toxicity was detected in any vital organ such as the liver,
kidney, brain, heart, and lung in cysteamine-treated mice when
evaluated by histological examination (Figure S3).
Cysteamine decreases MMP activity in primary
orthotopic tumors
MMP activity in primary orthotopic tumors was measured at
day 30. Cysteamine decreased MMPs activity in both tumors
(HS766T and MIA-PaCa2) at 100 and 250 mg/Kg cysteamine
doses (Figure 8A). In the same samples, we measured mRNA by q-
RT-PCR and protein levels of MMP-9 by ELISA. In contrast to in
vitro results, cysteamine did not affect mRNA and protein levels of
MMP-9 in primary tumors harvested from mice (Figure 8B and
8C). However, zymography assay for MMP-9 showed a dose
dependent decrease in gelatinase activity (Fig. 8D).
Discussion
We demonstrate that cysteamine inhibits pancreatic cancer cell
migration and invasion through direct inhibition of MMP
enzymatic activity in vitro. This newly discovered property of
cysteamine resulted in inhibition of metastasis of human
pancreatic cancer cells orthotopically implanted onto pancreas of
immunodeficient mice; the effect was cysteamine dose-dependent.
Cysteamine decreased not only the number of metastasis in the
peritoneal cavity, but also decreased the ascites generated by
aggressive pancreatic tumor metastasis. In contrast, no significant
change in the size or weight of the primary pancreatic tumor was
observed. Consistent with this observation, cysteamine did not
cause any effect on cell viability in pancreatic cancer lines up to a
concentration which caused significant inhibition of cell migration
and invasion. Mice treated with cysteamine survived longer
compared to control mice treated with excipient. Both in vitro and
in primary tumors in vivo, MMP enzymatic activity decreased with
cysteamine treatment while their expression at mRNA and protein
levels did not change. Zymographic results confirmed cysteamine
induced MMP inhibition in vitro and in vivo. These observations
indicate that blocking of catalytic activities of MMPs by
cysteamine is critical in the inhibition of tumor metastasis in
animal model of pancreatic cancer.
The anti-metastatic effects of cysteamine were mediated without
any visible signs of toxicity. Mice treated with even the highest
dose of cysteamine (250 mg/kg/day) displayed no adverse effects
related to general appearance, body weight, muscle damage,
serum enzymes and serum creatinine levels. In addition, major
organs from treated animals showed no evidence of histological
damage. These observations are consistent with the known safety
profile of cysteamine in humans [2,3]. Cysteamine caused only
gastrointestinal symptoms in subjects, as it increased gastric acid
production and decreased gastrointestinal motility [31]. However,
these effects were controlled by concomitant use of proton-pump
inhibitor [32]. It is noteworthy that cysteamine sufficiently
inhibited cancer cell migration and invasion in vitro at 50 mM, a
concentration that can be achieved in vivo. Oral administration of
cysteamine (given every 6 hours at 60 to 90 mg/kg of body weight
per day) can increase the cysteamine plasma level up to ,50 mM
[3,33–35]. In addition, 100 mg/kg/day s.c. injection of cyste-
amine in animals is similar to the dosage used for cystinosis, and
this dose produced a significant decrease in tumor metastasis and
prolongation of survival. We consider that cysteamine may be
safely administered in the clinic to control pancreatic cancer
metastasis.
Both mRNA and protein levels for MMP-9 were modestly to
moderately upregulated in vitro at the highest dose of cysteamine.
Similarly, mRNA of MMP-12 and 14 were also modestly
upregulated at the highest dose. This increase in MMP-9 was
not observed in vivo, perhaps because the pancreatic cancer cells
were incubated with cysteamine only for 24 hours, while in vivo
tumors were exposed to cysteamine continuously for 27 days. We
did not attempt to measure cysteamine levels in tumors in vivo
because intracellular metabolic fate of cysteamine in vivo is very
complex and difficult to measure as it binds to free thiol,
particularly the cysteines of cellular proteins. Instead, we depended
mainly on the biological effects of cysteamine on MMP activities
and tumor growth. Nevertheless, the increased MMP-9, MMP-12
and MMP-14 levels at the highest concentration in vitro may
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decrease of MMP activity by cysteamine. In contrast, the catalytic
activity of MMP-9 to hydrolyze gelatin in zymography assay did
not show such upregulation after treatment with highest dose of
cysteamine of pancreatic cancer cell lines in vitro as well as
orthotopic tumors in vivo. In fact in zymography assay for MMP-9,
cysteamine caused a dose dependent decrease in gelatinase
activity. These results suggest that enzymatic inhibition of
MMP-9 by cysteamine may be involved in decrease of invasion
and metastasis of pancreatic cancer. MMP1, MMP2, MMP7, and
MMP9 have also been shown to be expressed in pancreatic tumor
[36,37], but the effect of cysteamine on protein and mRNA levels
for all these MMPs was not examined except for MMP9. Thus,
present study lacks data on the effect of cysteamine on protein and
mRNA levels for all MMPs including MMP2. However, it is
important to point out that cysteamine inhibited enzymatic
activity of MMPs, which includes all MMPs.
The anti-MMP activity of cysteamine was lower than that of
specific MMP inhibitors such as batimastat and marimastat (IC50
nM to low mM compared to high mM range for cysteamine), but
cysteamine may be better tolerated in vivo. In fact, batimastat had
problems of poor oral bioavailability [24] and marimastat failed in
the clinic as higher dosage produced high musculoskeletal
toxicities and poor survival in patients with breast cancer
metastasis [38]. In the present study, mice tolerated up to
250 mg/kg/day cysteamine without any visible, biochemical or
histological evidence of toxicity or muscular damage.
In previous cancer treatment studies, cysteamine was used
because of its anti-oxidative and radio-protective effects [39].
During these studies, it was observed that cysteamine also had
anti-carcinogenic and anti-proliferative activities in a variety of
cancers. We now report that cysteamine exerts anti-MMP and
anti-metastatic effects. However, cysteamine did not affect the
primary pancreatic tumor size, suggesting that it should be used
concurrently with other anti-tumor agents such as gemcitabine for
optimal anticancer effects [13]. Based on these insights, we
propose that cysteamine can be useful as mono-therapy prior to
surgery to prevent metastasis, as an adjuvant, or as a component of
combination therapy for advanced stage disease to prolong
survival of patients with pancreatic cancer.
Supporting Information
Figure S1 Cysteamine inhibited cell invasion of pancre-
atic cancer cell lines. For the matrigel invasion assay, cells
were incubated with increasing concentrations of cysteamine in
the matrigel chamber for 24 hours, as for Figure 1A. The number
of invaded cells on the opposite side of the membrane was
counted. The average number was calculated in three individual
fields per the chamber and the data are expressed as mean 6 S.D.
of triplicate determinations.
(TIF)
Figure S2 Cysteamine inhibited cell migration of pan-
creatic cancer cell lines. For the wound healing assay, cells
were cultured until confluent and scratched using a sterilized
yellow tip. They were incubated for 24 hours with 0–5 mM of
cysteamine and the area of the wound between cell layers was
measured. Data are expressed as mean 6 S.D. of five different-
field determinations.
(TIF)
Figure S3 Histological analysis of vital organs in
cysteamine and control treated mice. Tumor-bearing
immunodeficient mice were treated with increasing doses of
cysteamine and vital organs (liver, kidney, brain, heart, and lung)
were harvested from each group at day 30 after treatment. Tissue
sections were analyzed by hematoxylin and eosin staining. No
organ toxicity by cysteamine was detected.
(TIF)
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